bluuebunny/crossref_metadata_2025_split huggingface dataset:
Hormonal treatment in pregnancy: A possible risk factor for neuroblastoma
Authors: Mandel M. , Toren A. , Rechavi G. , Dor J. , Ben‐Bassat I. , Neumann Y. 
Published: February 2007

AbstractIn the last 4 years, 24 cases of neuroblastoma were treated in the Pediatric Hematology‐Oncology Unit at the Chaim Sheba Medical Center, 8 of whom were under 1 year of age. Four of them were the product of a pregnancy‐induced or preserved by gonadotropins, clomiphene citrate, or progestational hormones. These drugs are known to produce a higher than normal level of estradiol or progestrone in the early stages of pregnancy. Our observation led to the hypothesis that high levels of progestational hormones given during pregnancy are a risk factor for neuroblastoma in infancy. © 1994 Wiley‐Liss, Inc.
Low grade malignant hemangioendothelioma of bone: A disease potentially curable with radiotherapy
Authors: Welles Laurie , Dorfman Howard , Valentine Edward S. , Wiernik Peter H. 
Published: February 2007

AbstractThis is a case of a young woman with a low grade malignant hemangioendothelioma of bone, who is considered cured after more than 8 years of follow‐up post radiotherapy. This patient demonstrates that, despite the characteristic multifocality of this rare tumor, treatment with radiotherapy alone can be curative. © 1994 Wiley‐Liss, Inc.
Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: A randomized study
Authors: Risseeuw‐Appel Inge M. , Dekker Ina , Hop Wim C. J. , Hählen Karel 
Published: February 2007

AbstractA randomized study was done in twenty newly diagnosed children with acute lymphoblastic leukemia. Ten children were treated with Escherichia coli L‐asparaginase, and ten with Erwinia chrysanthemi L‐asparaginase. L‐asparaginase (ASP) treatment started halfway during ALL‐induction treatment with vincristine, prednisone, daunorubicine and intrathecal methotrexate.The mean activated partial thromboplastin time (APTT) level in all children demonstrated a significant fall (P < 0.001) from 28.25 sec at diagnosis to 23.0 sec at the start of ASP treatment. In this same time interval, the mean fibrinogen level declined markedly from 3 g/l to 1.2 g/l (P < 0.001), probably due to prednisone therapy. The APTT stayed shortened during ASP therapy, whereas the hypofibrinogenemia recovered significantly faster in the Erwinia group (P ⩽ 0.01). Factors (F) II, V, VII and X stayed within the normal range, while F VIII and F IX were elevated. During the entire period of induction therapy, the ATIII activity remained within the normal range in both treatment groups. The protein C values, however, demonstrated a steady decline from 140% at start of ASP treatment to a mean of 81% and 93%, respectively, at the end of the ASP therapy in the E. coli and Erwinia group. Five of the ten children treated with E. coli ASP demonstrated protein C levels below 70% at the end of ASP therapy, opposed to none of the Erwinia treated patients (P = 0.03).We suggest that the effect of ASP resulting in decreased coagulationfactor synthesis is in part counterbalanced by the effect of prednisone on the coagulation system, when ASP is administered at the end of ALL induction treatment. The overall effect of ASP either of E. coli or of Erwinia on the hemorrhagic system reveals a slight imbalance towards thrombosis, mainly because of a gradual decrease in protein C activity. This imbalance is less pronounced in the Erwinia group. © 1994 Wiley‐Liss, Inc.
Ocular sequelae of multimodal therapy of hematologic malignancies in children
Authors: Pakisch B. , Langmann G. , Langmann A. , Slavc I. , Poier E. , Urban C. , Poschauko J. , Lackner H. , Knoblauch S. , Leitner H. , Dornbusch H. J. , Stücklschweiger G. , Raith J. , Hackl A. 
Published: February 2007

AbstractWe retrospectively analyzed the ocular findings after polychemotherapy including intrathecal methotrexate, systemic corticosteroids, and prophylactic cranial irradiation in children with acute lymphoblastic leukemia (n = 16) and non‐Hodgkin's lymphoma (n = 2). After a median surveillance time of 4.1 years, asymptomatic ocular abnormalities were observed in 83% of the patients: 7/18 had a decreased tear formation, 5/17 had an opacity of the vitreous body, and 13/18 had an opacity of the lens. It was not possible to determine retrospectively which therapy caused a particular effect. A comparison of the 2 irradiation techniques (with and without blocking of the lacrimal glands) showed that in 5/7 children who developed a reduced eye secretion, the lacrimal glands are within the treatment volume. Therefore, the reduced eye secretion is most likely radiation‐induced. Whereas the opacities of the vitreous body were caused by thrombopenia and bleeding during the course of disease, corticoid therapy might have contributed to the lens opacities. © 1994 Wiley‐Liss, Inc.
Treatment of advanced stage diffuse, small non‐cleaved cell lymphoma in childhood: Further experience with total therapy B
Authors: Griffin Timothy C. , Bowman W. Paul , Winick Naomi J. , Buchanan George R. 
Published: February 2007

AbstractPrior to the development of intensive treatments for patients with advanced stage B‐cell non‐Hodgkin's lymphoma (B‐NHL), the prognosis for such patients was dismal. A minority of patients attained long‐term, disease‐free survival. Since 1981, we have treated 28 children with advanced stage B‐NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high‐dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high‐dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B‐cell acute lymphoblastic leukemia and 26 had stage III B‐NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B‐ALL and 21 of 26 with stage III B‐NHL remain in CR, with a median follow‐up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T‐cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B‐NHL. The 2‐ and 5‐year event‐free survival rates were 85.7 ± 6.6% (SE) and 79.6 ± 8.5%, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B‐NHL without CNS involvement. © 1994 Wiley‐Liss, Inc.
Carboplatin and VP 16 in medulloblastoma: A phase II study of the French Society of Pediatric Oncology (sfop)
Authors: Gentet Jean Claude , Doz François , Bouffet Eric , Plantaz Dominique , Roché Henri , Tron Philippe , Kalifa Chantal , Mazingue Françhise , Sariban Eric , Chastagner Pascal , Bernard Jean‐Louis , Brunat‐Mentigny Maud , Raybaud Claude , Zucker Jean‐Michel 
Published: February 2007

AbstractThe purpose of this study is to evaluate the antitumor activity of combination carboplatin and etoposide in measurable medulloblastoma. From January '89 to January '92, 26 patients with medulloblastoma were included in a multicentric phase II study of 2 courses of carboplatin 160 mg/m2/d day 1 to day 5 and VP16 100 mg/m2/d day 1 to day 5. Median age was 10 years (19 months‐14.5 years). First treatment was surgery alone in 1 patient, surgery + radiotherapy in 4 patients, surgery + chemotherapy in 2 patients less than 3 years old, surgery + radiotherapy + chemotherapy in 19 patients (“8 drugs in 1 day” based:17, SIOP I:1, SIOP II:1). Previous treatment included cisplatin (20 cases), carboplatin (1 case), and VP16 (7 cases). Measurable disease was evaluated by CT scan, MRI or myelogram and CSF. Response rate (RR) was 72 ± 10%:8 complete responses (CR), 10 partial responses (PR), 1 objective effect (OE), 6 progressive disease (PD), 1 non‐evaluable. Thirty‐six courses were evaluated for toxicity. Median duration of WHO grade 4 neutropenia was 8 days (0–23). One patient died at day 18 after the first course because of diffuse haemorrhage during septic aplasia. Five other non‐life‐threatening septicemias were recorded. Median number of platelet transfusions was 1 (0–4). One child who had achieved a PR after two courses died from CNS bleeding after the third course. This drug combination achieves a high response rate in childhood medulloblastoma. Severe toxicity has been mainly encountered in previously heavily treated patients. Tolerance may be acceptable in newly diagnosed children, but careful hematological follow‐up and platelet transfusional support are definitely mandatory. © 1994 Wiley‐Liss, Inc.
Disseminated nonlymphoblastic lymphoma of childhood: A childrens cancer group study, CCG‐552
Authors: Finlay Jonathan L. , Anderson James R. , Cecalupo Anthony J. , Hutchinson Raymond J. , Kadin Marshall E. , Kjeldsberg Carl R. , Provisor Arthur J. , Woods William G. , Meadows Anna T. 
Published: February 2007

Abstract(1) Purpose: To assess the efficacy of a chemotherapy‐only regimen in pediatric patients with disseminated nonlymphoblastic lymphoma and acute B‐cell leukemia (B‐ALL).(2) Patients and Methods: Sixty‐eight eligible patients with previously untreated disseminated non‐lymphoblastic lymphoma were enrolled on a Childrens Cancer Group study. Therapy included cycles of chemotherapy, systemic and intrathecal (IT), ever 3 weeks for a total maximal duration of 57 weeks. Fifty‐five patients had small non‐cleaved cell lymphoma (SNCCL) and 13 had diffuse large cell lymphoma (DLCL). Forty‐seven were stage III, six were stage IV, and 15 had B‐ALL; 13 had central nervous system (CNS) involvement.(3) Results: Four year event‐free survival (EFS) was 53% (SE ± 12%). Stage III SNCCL patients with LDH < 500 IU/L achieved an improved EFS compared to other SNCCL patients (86% vs. 42% 4 year EFS, P = .072). The primary site of failure for advanced stage SNCCL patients was the CNS. All Ki‐1‐positive DLCL patients relapsed. Patterns of failure, time to relapse, and outcome following relapse differed between SNCCL and DLCL patients.(4) Conclusions: Advanced stage SNCCL requires better CNS‐directed chemotherapy to reduce the CNS failure rate; however, the achievement of durable disease‐free survival in four of 11 patients with CNS disease without use of cranial irradiation suggests merit for further evaluation of chemotherapy‐only strategies. DLCL patients do not need intensive CNS‐directed chemotherapy. © 1994 Wiley‐Liss, Inc.
High‐dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma
Authors: Kremens Bernhard , Klingebiel Thomas , Herrmann Friedrich , Bender‐Götze Christine , Burdach Stefan , Ebell Wolfram , Friedrich Wolfgang , Koscielniak Ewa , Schmid Hansjörg , Siegert Wolfgang , Suttorp Meinolf , Schaefer Ulrich W. , Berthold Frank 
Published: February 2007

AbstractTwenty‐six children with advanced neuroblastoma were consolidated with cisplatin, BCNU, etoposide, melphalan, 21 Gy of local radiotherapy, and bone marrow rescue in a multicenter study. All patients were over 1 year of age at diagnosis. Twenty‐two patients were treated in first complete or partial remission and four in second complete or partial remission. Hematologic rescue was autologous (n = 23), allogeneic (n = 2), or syngeneic (n = 1). Extrahematological toxicity involved primarily the gastrointestinal mucosa. Among five fatal toxicities, three included intestinal hemorrhage. Fourteen patients relapsed after BMT, four of them at the primary site. Seven children survive progression‐free after 16–56 months.These results are essentially not different from a single‐center study with the same protocol or from other published studies. The value of megatherapy for patients with advanced neuroblastoma or for a subgroup of them can only be established on a larger number of patients than most national trials accrue. © 1994 Wiley‐Liss, Inc.
Epstein‐barr virus (EBV) latent membrane protein (LMP) in tumor cells of Hodgkin's disease in pediatric patients
Authors: Preciado María Victoria , De Matteo Elena , Diez Blanca , Grinstein Saúl 
Published: February 2007

AbstractTwenty‐nine out of 31 consecutive pediatric patients with Hodgkin's disease treated at our hospital from 1988 to 1992 were studied. The selection criterion was the availability of sufficient formalin‐fixed, paraffin‐embedded tissue for analysis. Patient age ranged from 3 to 15 years with a median age of 7 years. Lymph node biopsies were examined for the presence of Epstein‐Barr virus (EBV)‐encoded latent membrane protein (LMP) in malignant cells by peroxidase immunolabeling. LMP positivity was present in 10/15 (67%) of mixed cellularity, 1/6 (17%) of lymphocyte predominance, 0/7 (0%) of nodular sclerosis, and 1/1 (100%) of lymphocyte depletion. Positive cases by age range were: 10/12 (83%) for 3–6 years and 2/17 (11%) for 7–15 years. The association between EBV and Hodgkin's disease in children appeared to be more frequent in patients with mixed cellularity and those in the 3–6 age range, though examples of EBV‐positive tumors were found in other histologic subtypes, stages and ages. Findings indicate that Hodgkin's disease in children is at least as strongly linked to EBV as in adults. Furthermore, we suggest that the EBV is associated with a subgroup of patients which can be defined on the basis of the age at diagnosis. © 1995 Wiley‐Liss, Inc.
High‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study
Authors: Fountzilas George , Skarlos Demosthenis , Katsohis Constantine , Pavlidis Nicholas , Giannakakis Theodoros , Bafaloukos Dimitrios , Fahantidis Epaminondas , Klouvas George , Beer Mario , Kosmidis Paris 
Published: February 2007

AbstractThe delivery of high‐dose epirubicin in patients with advanced breast cancer usually entails serious myelotoxicity and frequent treatment delays. Concurrent administration of G‐CSF probably allows the administration of epirubicin on schedule with minimal morbidity. From August 1990 to February 1992, 42 women with advanced breast cancer were treated with six cycles of epirubicin 110 mg/m2 every 4 weeks. Filgrastim 5 μg/kg per day for 14 days was administered subcutaneously starting 24 hours after chemotherapy. All patients had multiple metastatic sites, and 39 had visceral metastases. All cases were evaluable for response, toxicity, and survival. Treatment was delayed in only two cases. The actually administered average dose per unit time per patient amounted to 99.6% of the dose prescribed by the protocol. Two (4.5%; 95% confidence interval [C.I.] 0–16%) patients demonstrated a complete response and 14 (33%; 95% C.I. 19–49%) a partial response. Median time to progression was 31 weeks and median survival was 60 weeks. Severe granulocytopenia was seen in six patients; stomatitis and diarrhea in one patient each. Myoskeletal pain was noticed in 23 (55%) patients, while cardiac problems were reported in 3 cases. The present study shows that the prophylactic use of r‐met‐hu G‐CSF allows the administration of high‐dose epirubicin every 4 weeks with minimal morbidity and an improved quality of life. © 1995 Wiley‐Liss, Inc.
Isolated CNS metastasis as the first site of recurrence in a child with germ cell tumor of the mediastinum
Authors: Berkow Roger L. , Kelly David R. 
Published: February 2007

AbstractWe describe a 2‐year‐old black female who was previously in complete remission from a stage 4 mediastinal germ cell tumor (stage 4 because of a single pulmonary parenchymal lesion). She presented with headaches, obtundation, and brain herniation, and suffered sudden death 12 months after completing high‐dose chemotherapy. Autopsy revealed a large intraventricular lesion with mixed germ cell tumor elements, but no other evidence of malignancy was found. This case represents the first report of isolated CNS metastasis of malignant germ cell tumor in a child in apparent remission without evidence of advanced or recurrent disease in other sites. It is possible that the aggressive chemotherapy used resulted in a change in the natural history of this disorder. © 1995 Wiley‐Liss, Inc.
Recurrent venous thrombosis as the presenting manifestation of acute lymphocytic leukemia: Leukemic cell procoagulant activity is not responsible for the hypercoagulable state
Authors: Bilgrami Syed , Greenberg Bernard R. , Weinstein Ralph E. , Hair Gregory A. , Rickles Frederick R. 
Published: February 2007

AbstractThe association of cancer with clinical abnormalities of blood coagulation, including superficial thrombophlebitis, deep vein thrombosis (DVT), and disseminated intravascular coagulation (DIC) is well‐known, particularly in patients with solid tumors and acute promyelocytic leukemia (APL). Less commonly appreciated is the potential for the development of venous thromboembolic disease (TED) in patients with acute lymphocytic leukemia (ALL). Multiple mechanisms have been implicated for the activation of coagulation in these patients, with an emphasis on the contribution made by the procoagulant properties of the tumor cells themselves. We present two cases of patients with pre‐B cell ALL, both of whom developed recurrent TED as the presenting manifestation of their leukemia and/or heralding relapse. The blast cells from one of the patients were studied for the presence of procoagulant activity (PCA) and by Northern blot analysis for tissue factor (TF) messenger RNA (mRNA). Neither PCA nor TF mRNA could be identified in highly purified populations of the lymphoblast cells. We conclude that recurrent TED can be a manifestation of ALL and that mechanisms other than the release of tumor cell procoagulants should be sought to explain the pathogenesis of thrombosis in some patients. © 1995 Wiley‐Liss, Inc.
Consecutive glioblastoma and B cell non‐Hodgkin's lymphoma in a young child with von recklinghausen's neurofibromatosis
Authors: Uyttebroeck Anne , Legius Eric , Brock Penelope , Van De Casseye Willy , Casaer Paul , Van Daele Maria Casteels 
Published: February 2007

AbstractA young child with neurofibromatosis type 1 (NF1) is reported who developed two primary malignancies: a glioblastoma, followed 6 months later by an abdominal B cell non‐Hodgkin's lymphoma. The child is now 4.5 years off treatment and disease free, but has developed progressive and severe psychomotor retardation as sequelae. The NF1 gene is known to act as a tumor suppressor gene. The possible mechanisms leading to the occurrence of a second primary tumor in this child are discussed. © 1995 Wiley‐Liss, Inc.
Intrauterine monoclonal origin of neonatal concordant acute lymphoblastic leukemia in monozygotic twins
Authors: Mahmoud Hazem H. , Ridge Susan A. , Behm Frederick G. , Pui Ching‐Hon , Ford Anthony M. , Raimondi Susana C. , Greaves Melvin F. 
Published: February 2007

AbstractWe report detailed immunological, cytogenetic and molecular evidence for complete identity of the leukemic cell populations in monozygotic female twins with concordant leukemia diagnosed at two months of age. Both infants had early pre‐B acute lymphoblastic leukemia with the (11;19)(q23;p13) chromosomal translocation. A common clonal origin of leukemia in these infants was suggested by the finding of identical oligoclonal heavy chain immunoglobulin gene rearrangements. Leukemic cell DNA was examined for 11q23 rearrangements by Southern blotting and restriction fragments of identical size were found in the two cases, in contrast to the diversity of rearrangements observed in other unrelated and nontwinned control infants with t(11;19)(q23;p13). Similar restriction fragments were absent in blood mononuclear DNA from both parents, liver tissue from one twin and remission bone marrow of the other, indicating that the 11q23 rearrangement was acquired and not inherited as a chromosomal abnormality or polymorphism. These findings provide a definitive evidence for intrauterine single cell origin, with twin to twin transmission, of concordant leukemia in this infant twin pair. © 1995 Wiley‐Liss, Inc.
Wilms' tumor: A rational use of preoperative imaging
Authors: Ditchfield Michael R. , De Campo John F. , Waters Keith D. , Nolan Terrance M. 
Published: February 2007

AbstractObjective—To determine whether a preoperative imaging protocol relying predominantly on a chest X‐ray film (CXR) and ultrasound in patients with Wilms' tumor is adequate for patient management and to determine the frequency more sophisticated imaging, in particular, computed tomography (CT), is required. Design and setting—Historical cohort study at a tertiary pediatric hospital. Subjects—60 consecutive patients with Wilms' tumor treated at our institution between 1980 and 1990. Main outcome measure—The preoperative imaging was recorded and 2‐ and 4‐year survival were compared with the National Wilms' Tumor Study. Results—100% of patients had a preoperative CXR, 95% abdominal ultrasound, 5% abdominal CT, 13% chest CT, 47% abdominal X‐ray, 2% aortography, 5% cavography, and 35% intravenous urography. The overall 2‐ and 4‐year survivals of 92% and 90%, respectively, did not statistically differ from the National Wilms' Tumor Study 2‐ and 4‐year survivals of 94% and 91%. Conclusions—A preoperative imaging protocol relying predominantly on a CXR and abdominal ultrasound does not reduce survival. Other more sophisticated imaging, in particular, CT, is not required in the majority of cases and is warranted only when a CXR or ultrasound is unable to resolve relevant management problems. © 1995 Wiley‐Liss, Inc.
Juvenile chronic myelocytic leukemia—report of 10 cases
Authors: Arya Laxman S. , Bhatia Poonam , Jain Yogesh , Chaudhary Ved P. , Verma Ishwar C. , Chinnappan D. , Pati Har Prasad 
Published: February 2007

AbstractTen children (five boys and five girls) with juvenile chronic myelocytic leukemia were seen over a period of 12 years (1980–1991) at the All India Institute of Medical Sciences, New Delhi. With the exception of one who was aged 4.5 years, all children were below 4 years of age (mean age 20.4 months). The presenting features included fever, bleeding secondary to thrombocytopenia, marked hepatosplenomegaly, and skin rash. The striking hematological features were anemia, thrombocytopenia, peripheral blood monocytosis, and normoblastemia. There was no significant myeloid proliferation in the bone marrow aspirate (mean M:E = 5:1), while erythroid proliferation was prominent along with monocytosis (mean 11.2%). Fetal hemoglobin was raised in 8 of the 10 patients (mean 14.1%). Long‐term survival was poor, with maximum survival being 18 months in one case. New modalities of management of this rare entity are discussed. © 1995 Wiley‐Liss, Inc.
Papillary thyroid cancer with pulmonary metastases beginning in childhood: Clinical course over three decades
Authors: Vassilopoulou‐Sellin Rena , Libshitz Herman I. , Haynie Thomas P. 
Published: February 2007

AbstractWe present a case of childhood papillary thyroid cancer with persistent but stable pulmonary metastases for over three decades in order to highlight the natural history and clinical features of this unusual disease entity. A nine‐year‐old girl had thyroidectomy and cervical lymph node dissection followed by neck irradiation for invasive papillary thyroid cancer. Diffuse pulmonary metastases were present at the time of diagnosis and were treated with radioactive iodine 10 and 30 years later; both the chest radiographs and the patient remained stable throughout. This case illustrates the potential indolence of thyroid cancer when it presents during childhood. © 1995 Wiley‐Liss, Inc.